author-photo

Hugh Zhao

Fox Chase Cancer Center

8

Papers

663

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent

2012 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (33)
CEP-32496: A Novel Orally Active BRAF V600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

2012 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (39)
tumor-selective pharmacologic profile competitive with bortezomib CEP-18770: A novel, orally active proteasome inhibitor with a

2008
Show All
- Source
- Cite
- Save
Citations (0)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

2008 Blood
Show All
- Source
- Cite
- Save
Citations (213)
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

2006 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (42)
Trk inhibitors provide better efficacy than a VEGF-R kinase inhibitor in combination with gemcitabine on improving survival in an orthotopic model of human PDAC

2005 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

2004 Cancer Research
Show All
- Source
- Cite
- Save
Citations (148)
Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor

2003 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (188)